The cost effectiveness of penpulimab with paclitaxel and carboplatin in first-line treatment of metastatic squamous non-small cell lung cancer

The cost effectiveness of penpulimab with paclitaxel and carboplatin in first-line treatment of metastatic squamous non-small cell lung cancer

Abstract This study aimed to evaluate the cost-effectiveness of Penpulimab versus placebo in treating metastatic squamous non-small cell lung cancer (NSCLC) from the perspective of Chinese payers. A three-state Markov model was developed to simulate clinical efficacy and cost consumption using Kapla...

Full description

Saved in:
Bibliographic Details
Main Authors: Kaiqi Zhu, Zhaoyi Pan, Mengyao Qin, Jin Huang
Format: Article
Language:English
Published: Nature Portfolio 2025-04-01
Series:Scientific Reports
Subjects:
Penpulimab
Placebo
Non-Small cell lung Cancer
Cost-Effectiveness analysis
Markov model
Online Access:https://doi.org/10.1038/s41598-025-97591-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-97591-2

Similar Items